First-in-human case series of Embrace, a polyethylene glycol-based liquid embolic agent, utilisation for embolisation of arterial haemorrhage

Abstract Background: There are a number of liquid embolic agents available and in development for the use of endovascular embolization. The Embrace Hydrogel Embolic System (HES) is an aqueous polyethylene glycol (PEG)-based liquid embolic agent that has been used for the treatment of hypervascular tumours. This case series describes the first in human use of Embrace for the treatment of arterial haemorrhage. Case Presentation: 2 patients were enrolled into this study. The first patient was a 64 year old male and had active arterial pelvic haemorrhage after a motor vehicle accident and Embrace was used to stop the pelvic haemorrhage. The second patient was a 73 year old male had active bleeding from the right L4 lumbar artery whilst on therapeutic enoxaparin for a deep vein thrombosis that developed following excision of a L2/3 facet joint cyst 10 days prior. The technical success was 100% in stopping bleeding at the tie of procedure with no rebleeding to 30 days. Conclusions: In this small case series Embrace was successful in being able to stop active arterial bleeding. Further assessment of Embrace is underway in a larger multi-centre clinical trial.